CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non‐small cell lung cancer in vitro and in vivo

BACKGROUND: CM082 is a novel angiogenesis inhibitor targeting vascular endothelial growth factor receptor (VEGFR) and platelet‐derived growth factor receptor (PDGFR). The purpose of this research was to evaluate the antitumor activity of CM082 combined with gefitinib on epidermal growth factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Kun, Wang, Lili, Wei, Aili, Jia, Xinfei, Liu, Xiaoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262931/
https://www.ncbi.nlm.nih.gov/pubmed/32368855
http://dx.doi.org/10.1111/1759-7714.13430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262931/
https://www.ncbi.nlm.nih.gov/pubmed/32368855
http://dx.doi.org/10.1111/1759-7714.13430

Ejemplares similares